Tokyo, Nov. 19 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059813) titled 'Efficacy and Safety of Escalating Once-weekly Semaglutide from 0.5 mg to 1.0 mg in Type 2 Diabetes:A Retrospective Observational Study' on Nov. 18.
Study Type:
Observational
Primary Sponsor:
Institute - Toho University Omori Medical Center
Condition:
Condition - Type 2 diabetes mellitus
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate metabolic parameters and the incidence of adverse events before and after dose escalation in patients with diabetes whose dose of once-weekly semaglutide is increased from 0.5 mg to 1.0 mg, and thereby assess the efficacy ...